X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sonelokimab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
Sonelokimab is a novel tri-specific Nanobody® targeting IL 17A and IL-17F that also has an extended half-life and enhanced biodistribution through engineered binding affinity to albumin.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KY1005
Therapeutic Area: Dermatology Product Name: KY1005
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi Pasteur SA
Deal Size: $1,450.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 11, 2021
Details:
The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. KY1005 binds to OX40-Ligand and has the potential to treat a varieties of immune-mediated diseases and inflammatory disorders.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
